Insider trade

Director purchased ~$6.8K of BSX shares in the open market

Traded Aug 4, 2026 · Filed Aug 5, 2026

~$6.8K
Reported value · 140 sh @ $48.5879: 15K
Holds after · shares reported: -11.9%
stock since the trade · S&P 500 -0.9%, $49.09 → $43.23 on Oct 1

Why it stands out

A board member of Boston Scientific spent $6.8K of their very own money to buy Boston Scientific shares. 3 other people at Boston Scientific bought some too, in the same month.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 4, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 5, 2026

Director<$25KHoldings +1%4 insiders bought in 30d

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$6,802

Shares × reported transaction price

Size band

<$25K

Ownership change

+0.9%

Purchase shares ÷ estimated pre-transaction holdings, from the filing

Rarity

First purchase in 0 months

Confirmed open-market purchases by the same insider in the available history

Largest by this insider

No

Compared with 3 earlier confirmed purchases

Cluster activity

4 distinct insiders in 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Timing vs results

6 days after results of Jul 29, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $49.09 on Aug 4, 2026, 15% above its 52-week low and 55% below its high, after an 11% rise over the previous 30 trading days

52-week range $42.63 (Jul 14, 2026) to $108.14 (Sep 8, 2025), 10% of the way up, from 251 adjusted closes. 30 trading days earlier: $44.33 on Jun 22, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Mar 5, 2026 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

2 such cases were open. In re: Boston Scientific Corporation Securities Litigation, docket 1:26-cv-40075, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+4.8%	+1.2%	+3.6%
30 days	-8.8%	-0.3%	-8.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001225208-26-006951
Filed / recorded: Aug 5, 2026, 8:15 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: BOSTON SCIENTIFIC CORP
Issuer CIK: 885725
Ticker: BSX
Reporting person: David C Habiger
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Aug 4, 2026
Transaction code: P
Shares / units: 140
Price per share: $48.5879
Acquired / disposed: Acquired (A)
Shares owned after: 15,060
Ownership form: Direct
Amendment: No

Footnotes from the filing

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.54 to $48.60, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.